康龙化成“6·3”亡人事故引关注

Core Viewpoint - The investigation report on a safety incident at Kanglong Chemical, a leading CRO in China, reveals that two employees died due to asphyxiation during a production operation, highlighting significant management failures and safety protocol violations [2][3][4]. Company Overview - Kanglong Chemical (SZ300759) is a prominent CRO providing comprehensive R&D services to pharmaceutical companies, with a current stock price of 35.25 yuan and a market capitalization of 62.681 billion yuan [2]. Incident Details - The incident occurred on June 3, resulting in the deaths of two night shift operators during the crystallization experiment of a new drug, DP818. The accident was classified as a general production safety incident due to violations of operational protocols [2][3][4]. - The specific operation involved 248 steps, with the incident occurring during step 193, where operators were required to monitor and record temperatures [3]. Investigation Findings - The investigation identified that the operators failed to use an oxygen content detection device while releasing nitrogen gas, leading to their asphyxiation. The report indicated multiple management failures, including inadequate safety training and lack of adherence to safety protocols [4][5]. - The company’s management, including the COO, faces penalties, with suggested fines ranging from 20% to 50% of their annual salaries [5]. Financial Implications - Kanglong Chemical may face fines between 300,000 to 1 million yuan, which is relatively minor compared to its 2024 projected revenue of 12.276 billion yuan and net profit of 1.793 billion yuan [5]. Disclosure Obligations - The incident does not fall under mandatory disclosure requirements for listed companies as it is classified as a general accident. However, the company may still have obligations to disclose the incident if it significantly impacts financial performance or reputation [6].